Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 6, 2009 Brian Orelli	FDA to Search Engines: You Lose! FDA cracks down on pharma ads, but search engines are the real losers. The FDA wants the drugmakers to stop making claims in sponsored link advertisements.
BusinessWeek February 9, 2004 John Carey	Drug Ads Need Stronger Medicine New FDA guidelines may not go far enough in making sure pharmaceutical ads are used appropriately.
The Motley Fool June 5, 2008 Brian Lawler	Cancer Concerns Fuel FDA Inquiry The agency examines a class of blockbuster drugs for a link to cancer in young patients.
Pharmaceutical Executive December 1, 2005 Grant Winter	Inside DDMAC: A Conversation with Thomas Abrams Despite heightened scrutiny from industry advocates and the beginnings of self-imposed regulation, pharma companies' violations of DTC regulations have been getting worse, says the director of FDA's Division of Drug Marketing, Advertising, and Communications.
Pharmaceutical Executive November 1, 2005 Peter H. Nalen	Alternative Media: Targeting Audiences on the Web The most important web page to communicate with doctors and patients is the page of results that your potential customers see when they use search engines, such as Google, Yahoo!, or MSN.
InternetNews October 20, 2006 Roy Mark	'Net Vendors of Diabetes Cures on Notice The Federal Trade Commission and the Food and Drug Administration are teaming with Mexico and Canada to stop deceptive advertising and product sales of purported diabetes cures and treatments.
The Motley Fool September 8, 2008 Brian Orelli	Another FDA Safety Warning (Yawn) The FDA warning results from numerous reports of fungal infections in patients taking TNF inhibitors.
Chemistry World December 4, 2012 Andrew Turley	Drug R&D costs rising Inventing a new drug costs an enormous amount of money. It's part of the reason why the pharma industry is struggling to fill its pipelines. But we'd like to think that -- however slowly -- that cost is coming down. Unfortunately it isn't.
Food Processing February 2008 David Joy	Some health claims in jeopardy FDA is re-evaluating health claims for soy, antioxidant vitamins and fat-cancer.
Pharmaceutical Executive September 1, 2010	To Brand or Not to Brand? The effectiveness of direct-to-consumer prescription advertising hinges on a consumer's thirst for information. A new study intimates the less info consumers are given up front, the more they seem willing to learn.
Food Processing June 2009 Dave Fusaro	Do They Want Healthier Food or Not? Cheerios may have gone too far, but a `new' FDA should focus on safety and health.
BusinessWeek November 19, 2009 Catherine Arnst	Why Drugmakers Don't Twitter The FDA has so far failed to craft rules clarifying how pharmaceutical companies can participate in online discussions.
Nutra Solutions April 1, 2006 Kerry Hughes	Additions to Heart Health The Portolio Eating Plan successfully assembles key nutritional ingredients known to lower cholesterol into one diet.
Pharmaceutical Executive June 1, 2006 Philip A. George	Alternative Media: Online Med Sites Gain Patient Trust Pharma could benefit from a little less TV.
The Motley Fool May 13, 2009 Morgan Housel	Fool Blog: Call Me a Raging Drug Addict Really. I am. Cheerios, you see, should be classified as a drug, according to the FDA.
Pharmaceutical Executive August 1, 2006	Introduction: Pharm Exec at 25 A pharmaceuticals magazine celebrates its 25th anniversary.
Pharmaceutical Executive February 1, 2006 Chandler & Chicco	Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways
Food Processing December 2010 Diane Toops	Wellness Food Trends: Healthier Foods for the Heart Foods can be a solution (though carefully worded) for the leading cause of death.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
Nutrition Action Healthletter June 1999	Healing Broken Hearts Reversing heart disease with diet and exercise.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
BusinessWeek June 12, 2006 Catherine Arnst	Going From The Lab To Limbo The FDA has been delaying decisions on applications, and drugmakers are fuming.
Pharmaceutical Executive April 1, 2009 Patrick Clinton	Dear Commissioner... Unsolicited advice for FDA's next leader: Keep it real, fight popular delusions, and somehow, please, defend the agency.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
PC World June 2003 Anne Kandra	Consumer Watch: Avoid Online Snake Oil Sellers Learn how to find Internet medical advice that won't make you sick.
Pharmaceutical Executive August 1, 2008 George Koroneos	Hard of (Ad)hering Companies have responded to declining profits with a proliferation of patient compliance programs. But where is pharma in this paradigm shift?
Pharmaceutical Executive December 1, 2013	FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.
The Motley Fool November 23, 2009 Brian Orelli	The Side Effect of Developing Obesity Drugs The FDA is fickle when it comes to weight-loss drugs.
BusinessWeek January 30, 2006 Catherine Arnst	Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk.
Searcher June 2012 Stephanie C. Ardito	The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations.
Pharmaceutical Executive June 1, 2007 Clinton & Wechsler	The View From Inside Commissioner Andrew von Eschenbach on drug safety, DTC advertising, FDA's culture, and how the agency plans to bring itself into the age of molecular medicine.
The Motley Fool January 15, 2010 Brian Orelli	Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all.
Salon.com May 16, 2001 Janelle Brown	The poison pill The media, the government and the drug companies: They're all to blame for the fen-phen debacle, says "Dispensing With the Truth" author Alicia Mundy...
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
Pharmaceutical Executive August 1, 2006 Patrick Clinton	From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible.
Pharmaceutical Executive July 30, 2007	Direct to Consumer: Creativity Through Understanding Creative consumer campaigns begin with a clear understanding of pharma rules and regulations.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool June 28, 2010 Luke Timmerman	Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system.
Salon.com May 8, 2001 Daryl Lindsey	The "Joe Camel" ads of AIDS? The FDA says ads for drugs to suppress HIV are making false promises, and could be contributing to an epidemic of unsafe sex...
BusinessWeek November 29, 2004 Carey & Barrett	Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do.
Pharmaceutical Executive June 1, 2014 Jill Wechsler	What Price Innovation? Payers, drug plans seek clear assessment of drug value to rationalize high drug prices.
BusinessWeek October 18, 2004 Catherine Arnst	The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma
Managed Care June 2002	Oncologists: FDA needs to speed up approval of cancer-fighting drugs A Competitive Enterprise Institute survey of cancer specialists found that almost 8 of 10 oncologists think the FDA's approval process has "hurt their ability, at least once in their medical careers, to treat patients with the best possible care."
Pharmaceutical Executive April 1, 2007 Porth & Sillup	Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news.
Pharmaceutical Executive August 1, 2014 Jill Wechsler	Social Media Struggles Continue Tweeting limited, corrections okay, says FDA, as industry, regulators wrestle with the digital world.